Company intelligence / Profile preview

Lynx Therapeutics

Hayward, California, United States

Ownership: Private
Development stage: Other

Overview

Lynx Therapeutics developed a proprietary high-throughput DNA sequencing technology (Megaclone) that enabled advances in gene expression analysis and genomics research. The company played a role in developing and commercializing next-generation sequencing techniques. It became best known for its combination with Solexa, after which Solexa was acquired by Illumina, making the original platform foundational for modern, massively parallel sequencing.

Modalities: DNA sequencing technologyGenomics platform
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Lynx Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lynx Therapeutics.

Explore the full profile